Type 2 Diabetes Market Report 2026

The type 2 diabetes market size has grown strongly in recent years. It will grow from $51.47 billion in 2025 to $55.53 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising global obesity prevalence, increased sedentary lifestyles, expansion of oral antidiabetic drug availability, growing screening for metabolic disorders, improved access to primary diabetes care.

The type 2 diabetes market size is expected to see strong growth in the next few years. It will grow to $78.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing demand for weight-management focused therapies, rising adoption of personalized diabetes treatment plans, expansion of digital therapeutic platforms, growing focus on preventive diabetes management, increasing investments in next-generation antidiabetic drugs. Major trends in the forecast period include increasing adoption of glp-1 receptor agonists, rising focus on cardiometabolic risk management, growing use of combination drug therapies, expansion of lifestyle-integrated treatment approaches, enhanced emphasis on long-term glycemic control.

Rising rates of obesity and heart disease are expected to drive the growth of the type 2 diabetes market going forward. Obesity is a condition characterized by excessive body fat accumulation to unhealthy levels, while heart disease encompasses various conditions affecting the heart and blood vessels. Excess body weight increases the likelihood of insulin resistance, which can lead to elevated blood sugar levels and the onset of type 2 diabetes. Conversely, high blood sugar levels can harm blood vessels and nerves that regulate the heart and circulatory system, contributing to heart disease. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that roughly one in eight people globally were affected by obesity. This included 2.5 billion adults (aged 18 and older) who were overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under the age of five were overweight. Therefore, the increasing prevalence of obesity and heart disease is propelling the growth of the type 2 diabetes market.

Leading companies in the type 2 diabetes market are concentrating on developing innovative therapies, such as extended-indication SGLT2/GLP-1 combination treatments, to improve glycemic control, reduce comorbidities, and enhance patient adherence. Extended-indication SGLT2/GLP-1 combination therapies involve pharmaceutical regimens that combine sodium-glucose co-transporter-2 (SGLT2) inhibitors with glucagon-like peptide-1 (GLP-1) receptor agonists (or fixed-dose combinations) to simultaneously manage blood glucose, obesity, cardiovascular, and renal outcomes in patients with type 2 diabetes. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, received FDA approval in the U.S. for Farxiga (dapagliflozin) for pediatric type 2 diabetes (ages 10 and older), expanding its use beyond adults and targeting a wider patient population. This advancement provides once-daily oral dosing for younger patients, integrates cardiometabolic and renal protection data, and expands the market into pediatric and early-stage type 2 diabetes segments, driving growth in the global type 2 diabetes market.

In January 2024, Roche Group, a Switzerland-based healthcare company, acquired Carmot Therapeutics for an undisclosed sum. Through this acquisition, Roche gains access to Carmot’s existing R&D portfolio, including all clinical and preclinical assets, as well as exclusive rights to Carmot’s Chemotype Evolution discovery platform in metabolism, further enhancing Roche’s R&D capabilities and portfolio across cardiovascular and metabolic diseases. Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative therapies for individuals with obesity and diabetes.

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health.

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the type 2 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the type 2 diabetes market by increasing costs of imported active pharmaceutical ingredients, finished formulations, injection devices, and packaging materials used across oral and injectable therapies. Pharmaceutical manufacturers and healthcare systems in North America and Europe are most affected due to reliance on international drug supply chains, while Asia-Pacific faces higher export and production costs. These tariffs are contributing to pricing pressures and delayed product launches. At the same time, they are supporting local API manufacturing, regional formulation facilities, and domestic pharmaceutical innovation.

The type 2 diabetes market research report is one of a series of new reports that provides type 2 diabetes market statistics, including type 2 diabetes industry global market size, regional shares, competitors with a type 2 diabetes market share, detailed type 2 diabetes market segments, market trends and opportunities, and any further data you may need to thrive in the type 2 diabetes industry. This type 2 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Type 2 diabetes is a long-term metabolic disorder marked by high blood sugar levels resulting from insulin resistance and insufficient insulin production. Its onset is influenced by a combination of genetic, lifestyle, and environmental factors. Managing type 2 diabetes can involve dietary and pharmaceutical interventions, including weight reduction, a healthy diet, and regular exercise.

The main categories of drug classes for type 2 diabetes include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas and other insulin secretagogues, biguanides, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and others. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral medications that work by blocking the enzyme that breaks down incretin hormones, which help regulate blood sugar levels. They are applied for various purposes, including glycemic control, cardiovascular safety, and avoidance of hypoglycemia, and are used by different end-users such as children and adults.

The type 2 diabetes market consists of revenues earned by entities by providing services such as blood sugar monitoring, diabetes education and support, bariatric surgery and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The type 2 diabetes market also includes sales of blood glucose meters, insulin pens, insulin syringes, insulin pumps, metformin and diabetic socks. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.